CFO steps down at cancer diagnostics firm Precipio
PHOTO | Pixabay.com
New Haven biotech Precipio, Inc., announced Tuesday that CFO Carl Iberger would resign this week.
“Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO,” the company said in a statement.
Precipio’s CEO Ilan Danieli said, “Carl has been a pillar of stability, guidance, and support to the Company, and to me personally, and has enabled me the privilege of focusing on growing the business, knowing that the company’s financial matters are in his extremely capable hands.”
Matt Gage, Precipio’s director of financial reporting and analysis, was named interim CFO. Gage joined Precipio following its acquisition of Transgenomic in 2017 and has managed the firm’s accounting functions and public filings.
Precipio has developed an alternative cancer diagnostics platform that promises more accurate and personalized results.
Contact Liese Klein at lklein@newhavenbiz.com.
Most Recent
Most Recent
0 Comments